Life Science microcap investors may want to take a look at Cash Rich Chiasma (CHMA:NASD $1.35). I estimate current net cash near USD $66M or $2.69/share. They need to bring down their burn rate but maybe they will eventually leverage this war chest of cash to rebuild shareholder value.
Qtrly Burn – Approx. $7.5M / Shares Out: 24.5 million
2016 they spent $31M on R&D and $22M on G&A
Chiasma is focused on improving the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections.